Latigo Biotherapeutics (NASDAQ:LTGO) Shares Up 4.9% – What’s Next?

Shares of Latigo Biotherapeutics, Inc. (NASDAQ:LTGO) rose 4.9% on Wednesday . The company traded as high as $23.75 and last traded at $23.68. 37,816 shares were traded during trading, a decline of 83% from the average session volume of 223,493 shares. The stock had previously closed at $22.57.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Latigo Biotherapeutics to a “hold” rating in a research note on Saturday, August 15th.

Latigo Biotherapeutics Price Performance

Insider Activity at Latigo Biotherapeutics

In related news, Director James B. Tananbaum acquired 140,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, with a total value of $2,520,000.00. Following the completion of the acquisition, the director owned 2,008,024 shares in the company, valued at approximately $36,144,432. This represents a 7.49% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Foresite Capital Management V, purchased 140,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider owned 2,008,024 shares in the company, valued at approximately $36,144,432. This trade represents a 7.49% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. Its lead product candidate includes LTG-001. Latigo Biotherapeutics Inc is based in THOUSAND OAKS, Calif.